Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
Stocks · News reference
Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $68
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $60 to $68.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and maintains $70 price target.
8-K filing — Eton Pharmaceuticals, Inc. (ETON)
Filed: 2026-10-14 AccNo: 0001437749-26-032600 Size: 242 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 9.01: Financial Statements and Exhibits
Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient